A STAT Protein Domain That Determines DNA Sequence Recognition Suggests a Novel DNA-Binding Domain
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models
Author Manuscript Published OnlineFirst on September 25, 2018; DOI: 10.1158/1535-7163.MCT-18-0508 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models Florian Handle1,2, Martin Puhr1, Georg Schaefer3, Nicla Lorito1, Julia Hoefer1, Martina Gruber1, Fabian Guggenberger1, Frédéric R. Santer1, Rute B. Marques4, Wytske M. van Weerden4, Frank Claessens2, Holger H.H. Erb5*, Zoran Culig1* 1 Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria 2 Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium 3 Department of Pathology, Medical University of Innsbruck, Innsbruck, Austria 4 Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands 5 Department of Urology and Pediatric Urology, University Medical Center Mainz, Mainz, Germany *Joint senior authors Running title: Galiellalactone reduces IL6-mediated AR activity Conflict of interest statement: Zoran Culig received research funding and honoraria from Astellas. Other authors declare no potential conflict of interest. Keywords (5): Prostate cancer, androgen receptor, Interleukin-6, STAT3, galiellalactone Financial support: This work was supported by grants from the Austrian Cancer Society/Tirol (to F. Handle) and the Austrian Science Fund (FWF): W1101-B12 (to Z. Culig). Corresponding author: Prof. Zoran Culig, Medical University of Innsbruck, Division of Experimental Urology, Anichstr. 35 6020 Innsbruck, Austria, [email protected] Word counts: Abstract: 242 (limit: 250); Text: 4993 (limit: 5000) Handle et al., 2018 1 Downloaded from mct.aacrjournals.org on October 1, 2021. -
Quantitative Modelling Explains Distinct STAT1 and STAT3
bioRxiv preprint doi: https://doi.org/10.1101/425868; this version posted September 24, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title Quantitative modelling explains distinct STAT1 and STAT3 activation dynamics in response to both IFNγ and IL-10 stimuli and predicts emergence of reciprocal signalling at the level of single cells. 1,2, 3 1 1 1 1 1 2 Sarma U , Maitreye M , Bhadange S , Nair A , Srivastava A , Saha B , Mukherjee D . 1: National Centre for Cell Science, NCCS Complex, Ganeshkhind, SP Pune University Campus, Pune 411007, India. 2 : Corresponding author. [email protected] , [email protected] 3: Present address. Labs, Persistent Systems Limited, Pingala – Aryabhata, Erandwane, Pune, 411004 India. bioRxiv preprint doi: https://doi.org/10.1101/425868; this version posted September 24, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Abstract Cells use IFNγ-STAT1 and IL-10-STAT3 pathways primarily to elicit pro and anti-inflammatory responses, respectively. However, activation of STAT1 by IL-10 and STAT3 by IFNγ is also observed. The regulatory mechanisms controlling the amplitude and dynamics of both the STATs in response to these functionally opposing stimuli remains less understood. Here, our experiments at cell population level show distinct early signalling dynamics of both STAT1 and STAT3(S/1/3) in responses to IFNγ and IL-10 stimulation. -
Locating Mammalian Transcription Factor Binding Sites: a Survey of Computational and Experimental Techniques
Downloaded from genome.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press Review Locating mammalian transcription factor binding sites: A survey of computational and experimental techniques Laura Elnitski,1,4 Victor X. Jin,2 Peggy J. Farnham,2 and Steven J.M. Jones3 1Genomic Functional Analysis Section, National Human Genome Research Institute, National Institutes of Health, Rockville, Maryland 20878, USA; 2Genome and Biomedical Sciences Facility, University of California–Davis, Davis, California 95616-8645, USA; 3Genome Sciences Centre, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada V5Z-4E6 Fields such as genomics and systems biology are built on the synergism between computational and experimental techniques. This type of synergism is especially important in accomplishing goals like identifying all functional transcription factor binding sites in vertebrate genomes. Precise detection of these elements is a prerequisite to deciphering the complex regulatory networks that direct tissue specific and lineage specific patterns of gene expression. This review summarizes approaches for in silico, in vitro, and in vivo identification of transcription factor binding sites. A variety of techniques useful for localized- and high-throughput analyses are discussed here, with emphasis on aspects of data generation and verification. [Supplemental material is available online at www.genome.org.] One documented goal of the National Human Genome Research and other regulatory elements is mediated by DNA/protein in- Institute (NHGRI) is the identification of all functional noncod- teractions. Thus, one major step in the characterization of the ing elements in the human genome (ENCODE Project Consor- functional elements of the human genome is the identification tium 2004). -
Specificity Landscapes Unmask Submaximal Binding Site Preferences of Transcription Factors
Specificity landscapes unmask submaximal binding site preferences of transcription factors Devesh Bhimsariaa,b,1, José A. Rodríguez-Martíneza,2, Junkun Panc, Daniel Rostonc, Elif Nihal Korkmazc, Qiang Cuic,3, Parameswaran Ramanathanb, and Aseem Z. Ansaria,d,4 aDepartment of Biochemistry, University of Wisconsin–Madison, Madison, WI 53706; bDepartment of Electrical and Computer Engineering, University of Wisconsin–Madison, Madison, WI 53706; cDepartment of Chemistry, University of Wisconsin–Madison, Madison, WI 53706; and dThe Genome Center of Wisconsin, University of Wisconsin–Madison, Madison, WI 53706 Edited by Michael Levine, Princeton University, Princeton, NJ, and approved September 24, 2018 (received for review July 13, 2018) We have developed Differential Specificity and Energy Landscape Here, we report the development of Differential Specificity (DiSEL) analysis to comprehensively compare DNA–protein inter- and Energy Landscapes (DiSEL) to compare experimental actomes (DPIs) obtained by high-throughput experimental plat- platforms, computational methods, and interactomes of TFs, forms and cutting edge computational methods. While high-affinity especially those factors that bind identical consensus motifs. Our DNA binding sites are identified by most methods, DiSEL uncovered results reveal that (i) most high-throughput experimental plat- nuanced sequence preferences displayed by homologous transcription forms reliably identify high-affinity motifs but yield less reliable factors. Pairwise analysis of 726 DPIs uncovered homolog-specific dif- information on submaximal sites; (ii) with few exceptions, com- ferences at moderate- to low-affinity binding sites (submaximal sites). putational methods model DPIs with a focus on high-affinity DiSEL analysis of variants of 41 transcription factors revealed that sites; (iii) submaximal sites improve the annotation of biologi- many disease-causing mutations result in allele-specific changes in cally relevant binding sites across genomes; (iv) among members binding site preferences. -
DNA Sequencing and Sorting: Identifying Genetic Variations
BioMath DNA Sequencing and Sorting: Identifying Genetic Variations Student Edition Funded by the National Science Foundation, Proposal No. ESI-06-28091 This material was prepared with the support of the National Science Foundation. However, any opinions, findings, conclusions, and/or recommendations herein are those of the authors and do not necessarily reflect the views of the NSF. At the time of publishing, all included URLs were checked and active. We make every effort to make sure all links stay active, but we cannot make any guaranties that they will remain so. If you find a URL that is inactive, please inform us at [email protected]. DIMACS Published by COMAP, Inc. in conjunction with DIMACS, Rutgers University. ©2015 COMAP, Inc. Printed in the U.S.A. COMAP, Inc. 175 Middlesex Turnpike, Suite 3B Bedford, MA 01730 www.comap.com ISBN: 1 933223 71 5 Front Cover Photograph: EPA GULF BREEZE LABORATORY, PATHO-BIOLOGY LAB. LINDA SHARP ASSISTANT This work is in the public domain in the United States because it is a work prepared by an officer or employee of the United States Government as part of that person’s official duties. DNA Sequencing and Sorting: Identifying Genetic Variations Overview Each of the cells in your body contains a copy of your genetic inheritance, your DNA which has been passed down to you, one half from your biological mother and one half from your biological father. This DNA determines physical features, like eye color and hair color, and can determine susceptibility to medical conditions like hypertension, heart disease, diabetes, and cancer. -
Signal Transducer and Activator of Transcription 5A/B in Prostate and Breast Cancers
Endocrine-Related Cancer (2008) 15 367–390 REVIEW Signal transducer and activator of transcription 5A/B in prostate and breast cancers Shyh-Han Tan and Marja T Nevalainen Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, BLSB 309, Philadelphia, Pennsylvania 19107, USA (Correspondence should be addressed to M T Nevalainen; Email: [email protected]) Abstract Protein kinase signaling pathways, such as Janus kinase 2-Signal transducer and activator of transcription 5A/B (JAK2-STAT5A/B), are of significant interest in the search for new therapeutic strategies in both breast and prostate cancers. In prostate cancer, the components of the JAK2- STAT5A/B signaling pathway provide molecular targets for small-molecule inhibition of survival and growth signals of the cells. At the same time, new evidence suggests that the STAT5A/B signaling pathway is involved in the transition of organ-confined prostate cancer to hormone- refractory disease. This implies that the active JAK2-STAT5A/B signaling pathway potentially provides the means for pharmacological intervention of clinical prostate cancer progression. In addition, active STAT5A/B may serve as a prognostic marker for identification of those primary prostate cancers that are likely to progress to aggressive disease. In breast cancer, the role of STAT5A/B is more complex. STAT5A/B may have a dual role in the regulation of malignant mammary epithelium. Data accumulated from mouse models of breast cancer suggest that in early stages of breast cancer STAT5A/B may promote malignant transformation and enhance growth of the tumor. This is in contrast to established breast cancer, where STAT5A/B may mediate the critical cues for maintaining the differentiation of mammary epithelium. -
CHD7 Represses the Retinoic Acid Synthesis Enzyme ALDH1A3 During Inner Ear Development
CHD7 represses the retinoic acid synthesis enzyme ALDH1A3 during inner ear development Hui Yao, … , Shigeki Iwase, Donna M. Martin JCI Insight. 2018;3(4):e97440. https://doi.org/10.1172/jci.insight.97440. Research Article Development Neuroscience CHD7, an ATP-dependent chromatin remodeler, is disrupted in CHARGE syndrome, an autosomal dominant disorder characterized by variably penetrant abnormalities in craniofacial, cardiac, and nervous system tissues. The inner ear is uniquely sensitive to CHD7 levels and is the most commonly affected organ in individuals with CHARGE. Interestingly, upregulation or downregulation of retinoic acid (RA) signaling during embryogenesis also leads to developmental defects similar to those in CHARGE syndrome, suggesting that CHD7 and RA may have common target genes or signaling pathways. Here, we tested three separate potential mechanisms for CHD7 and RA interaction: (a) direct binding of CHD7 with RA receptors, (b) regulation of CHD7 levels by RA, and (c) CHD7 binding and regulation of RA-related genes. We show that CHD7 directly regulates expression of Aldh1a3, the gene encoding the RA synthetic enzyme ALDH1A3 and that loss of Aldh1a3 partially rescues Chd7 mutant mouse inner ear defects. Together, these studies indicate that ALDH1A3 acts with CHD7 in a common genetic pathway to regulate inner ear development, providing insights into how CHD7 and RA regulate gene expression and morphogenesis in the developing embryo. Find the latest version: https://jci.me/97440/pdf RESEARCH ARTICLE CHD7 represses the retinoic acid synthesis enzyme ALDH1A3 during inner ear development Hui Yao,1 Sophie F. Hill,2 Jennifer M. Skidmore,1 Ethan D. Sperry,3,4 Donald L. -
Oncjuly3 6..6
Oncogene (1999) 18, 4137 ± 4143 ã 1999 Stockton Press All rights reserved 0950 ± 9232/99 $12.00 http://www.stockton-press.co.uk/onc Tax protein of HTLV-1 inhibits CBP/p300-mediated transcription by interfering with recruitment of CBP/p300 onto DNA element of E-box or p53 binding site Takeshi Suzuki1, Masami Uchida-Toita1 and Mitsuaki Yoshida*,1 1Department of Cellular and Molecular Biology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan Tax protein of human T-cell leukemia virus type 1 Tax was originally identi®ed as a transcriptional (HTLV-1) is a potent transcriptional regulator which can activator for viral gene expression and then was shown activate or repress speci®c cellular genes and has been to activate a wide variety of cellular genes (Yoshida et proposed to contribute to leukemogenic processes in al., 1995). Tax was also demonstrated to inhibit adult T-cell leukemia. The molecular mechanism of Tax- expression of several genes. In addition to the mediated trans-activation has been well investigated. transcriptional deregulation, we found that Tax binds However, trans-repression by Tax remains to be studied to p16ink4a protein, a cyclin-dependent kinase (CDK) in detail, although it is known to require a speci®c DNA inhibitor, and suppresses its inhibitory activity pre- element such as E-box or p53 binding site. Examining venting the cell from undergoing growth arrest (Suzuki possible mechanisms of trans-repression, we found that et al., 1996). These pleiotropic functions of Tax aect co-expression of E47 and p300 activated E-box multiple regulatory processes of cells and are believed dependent transcription and this activation was eciently to play roles at least in the initial stage of repressed by Tax. -
Transcrip\Onal and Epigene\C Changes During Heart Disease
786/110 Transcrip)onal and Epigene)c Changes during Heart Disease Danish Sayed Unique Features of Heart • Involuntary, rhythmic, cyclic contractions • Terminally differentiated, postnatal myocytes increase in size not numbers for growth • Number of non myocytes (e.g. fibroblasts) is more (60-70%) compared to number of myocytes (~30%). Neonate Heart Postnatal Growth “Physiological” Adult Heart - Exercise - Hypertension - Pregnancy - Aortic Stenosis - Sarcomeric Gene mutation - Myocardial Infarction - Dilated Cardiomyopathy Physiological Pathological Hypertrophy Hypertrophy Dilatation and Failure Compensatory Decompensation Overload • Increase in cardiomyocyte size • Chamber dilatation and mass, resulting in enlarged heart • Decreased Ventricular Wall • Increase in generalized gene Thickness and Increased expression, superimposed with wall tension significant increase in specialized genes, fetal gene • Altered Ca+2 handling program • Increased wall thickness • Increased myocardial • Switch to glucose metabolism apoptosis for energy Compromised Maintained Cardiac Cardiac function and Function and Output Output Modulators of Cardiac Hypertrophy L-Type Ca+2 Ang II, ET-1 Channel α-Adrenergic β-Adrenergic Mechanical Ca+2 Insulin-like Growth Stretch + Factor Na Gq Gs P Ca+2 PKA PLC Adenylyl Integrin Cyclase Ca+2 RAS-GTP Na+ PI3K IP3 DAG cAMP Calcineurine FAK AKT Ca+2 Rho PKC PKA Ras mTOR Rac GSK3β 4EBP1 Rock MLCK NFAT MAPK eIF2B p70S6K eIF4E ME ME ME ME GATA4 GATA4 MEF2 Sarcomere SRF Translation AC AC Transcription HDAC Histone Acetylation HAT Modificatn. Methylation HMT Chromatin Demethylases Remodeling Phosphorylation DNA Methylation Transcriptional Modificatn. General Factors Transcription factors TFIIA, TFIIB, TFIID… Promoter Specific Factors GATA family, NFATc family Activity Recruitment Gene Regulation RNA Polymerase II Dynamics Initiation Elongation Translation factors e.g. -
Transcription Factor IRF8 Directs a Silencing Programme for TH17 Cell Differentiation
ARTICLE Received 17 Aug 2010 | Accepted 13 Apr 2011 | Published 17 May 2011 DOI: 10.1038/ncomms1311 Transcription factor IRF8 directs a silencing programme for TH17 cell differentiation Xinshou Ouyang1, Ruihua Zhang1, Jianjun Yang1, Qingshan Li1, Lihui Qin2, Chen Zhu3, Jianguo Liu4, Huan Ning4, Min Sun Shin5, Monica Gupta6, Chen-Feng Qi5, John Cijiang He1, Sergio A. Lira1, Herbert C. Morse III5, Keiko Ozato6, Lloyd Mayer1 & Huabao Xiong1 TH17 cells are recognized as a unique subset of T helper cells that have critical roles in the pathogenesis of autoimmunity and tissue inflammation. Although OR Rγt is necessary for the generation of TH17 cells, the molecular mechanisms underlying the functional diversity of TH17 cells are not fully understood. Here we show that a member of interferon regulatory factor (IRF) family of transcription factors, IRF8, has a critical role in silencing TH17-cell differentiation. Mice with a conventional knockout, as well as a T cell-specific deletion, of the Irf8 gene exhibited more efficient TH17 cells. Indeed, studies of an experimental model of colitis showed that IRF8 deficiency resulted in more severe inflammation with an enhanced TH17 phenotype. IRF8 was induced steadily and inhibited TH17-cell differentiation during TH17 lineage commitment at least in part through its physical interaction with RORγt. These findings define IRF8 as a novel intrinsic transcriptional inhibitor of TH17-cell differentiation. 1 Immunology Institute, Department of Medicine, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, New York 10029, USA. 2 Department of Pathology, Mount Sinai School of Medicine, New York, New York 10029, USA. -
Repressor to Activator Switch by Mutations in the First Zn Finger of The
Proc. Nat!. Acad. Sci. USA Vol. 88, pp. 7086-7090, August 1991 Biochemistry Repressor to activator switch by mutations in the first Zn finger of the glucocorticoid receptor: Is direct DNA binding necessary? (interleukin 1 indudbility/dexamethasone modulation/DNA-binding domain mutants/interleukin 6 and c-fos promoters) ANURADHA RAY, K. STEVEN LAFORGE, AND PRAVINKUMAR B. SEHGAL* The Rockefeller University, New York, NY 10021 Communicated by Igor Tamm, May 20, 1991 (receivedfor review March 15, 1991) ABSTRACT Transfection ofHeLa cells with cDNA vectors previous experiments in HeLa cells transfected with cDNA expressing the wild-type human glucocorticoid receptor (GR) vectors constitutively expressing the wild type (wt) but not enabled dexamethasone to strongly repress cytokine- and sec- the inactive carboxyl-terminal truncation mutants of GR, we ond messenger-induced expression of cotransfected chimeric observed that dexamethasone (Dex) strongly repressed the reporter genes containing transcription regulatory DNA ele- induction by interleukin 1 (IL-1), tumor necrosis factor, ments from the human interleukin 6 (IL-6) promoter. Deletion phorbol ester, or forskolin of IL-6-chloramphenicol acetyl- of the DNA-binding domain or of the second Zn finger or a transferase (CAT) constructs containing IL-6 DNA from point mutation in the Zn catenation site in the second finger -225 to +13. Dex also repressed induction of IL-6- blocked the ability of GR to mediate repression of the IL-6 thymidine kinase (TK)-CAT chimeric constructs containing promoter. -
Expression of Androgen Receptor Coregulators in Prostate Cancer
1032 Vol. 10, 1032–1040, February 1, 2004 Clinical Cancer Research Expression of Androgen Receptor Coregulators in Prostate Cancer Marika J. Linja,1 Kati P. Porkka,1 Conclusions: These findings suggest that the decreased Zhikang Kang,3 Kimmo J. Savinainen,1 expression of PIAS1 and SRC1 could be involved in the progression of prostate cancer. In addition, gene amplifica- Olli A. Ja¨nne,3 Teuvo L. J. Tammela,2 4 3 tion of SRC1 in one of the xenografts implies that, in some Robert L. Vessella, Jorma J. Palvimo, and tumors, genetic alteration of SRC1 may provide a growth 1 Tapio Visakorpi advantage. 1Laboratory of Cancer Genetics, Institute of Medical Technology and 2Department of Urology, University of Tampere and Tampere University Hospital, Tampere, Finland; 3Institute of Biomedicine, INTRODUCTION 4 University of Helsinki, Helsinki, Finland; and Department of The critical role of androgens in the development of pros- Urology, University of Washington, Seattle, Washington tate cancer is indicated, for example, by the fact that prostate cancer does not develop in men castrated early in their life (1). ABSTRACT In addition, more that 50 years ago, Huggins and Hodges (2) Purpose: The androgen receptor (AR)-mediated signal- showed that hormonal therapy is an effective treatment for ing pathway seems to be essentially involved in the develop- prostate cancer. Subsequently, androgen withdrawal has become ment and progression of prostate cancer. In vitro studies the standard and is practically the only effective treatment for have shown that altered expression of AR coregulators may advanced prostate cancer. Although most prostate carcinomas significantly modify transcriptional activity of AR, suggest- are originally androgen dependent, they eventually become hor- ing that these coregulators could also contribute to the mone refractory during treatment (3).